Foster Dykema Cabot & Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$25.8M	Sell	57,792 -552	-0.9%	-$257K	1.64%	19
2025 Q4	$26.5M	Sell	58,344 -2,345	-4%	-$1.01M	1.63%	19
2025 Q3	$23.8M	Sell	60,689 -234	-0.4%	-$97.8K	1.56%	22
2025 Q2	$27.1M	Sell	60,923 -532	-0.9%	-$245K	1.91%	19
2025 Q1	$29.8M	Buy	61,455 +591	+1%	+$275K	2.39%	14
2024 Q4	$24.5M	Buy	60,864 +1,094	+2%	+$507K	1.91%	19
2024 Q3	$27.8M	Sell	59,770 -205	-0.3%	-$98.5K	2.33%	13
2024 Q2	$28.1M	Buy	59,975 +250	+0.4%	+$109K	2.51%	11
2024 Q1	$25M	Buy	59,725 +2,299	+4%	+$972K	2.33%	16
2023 Q4	$23.4M	Buy	+57,426	New	+$21.2M	2.48%	10

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Foster Dykema Cabot & Partners's VRTX Position: Q1 2026 in Review

Foster Dykema Cabot & Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 0.95% in Q1 2026, selling an estimated $257K and leaving 57,792 shares worth $25.8M. The position accounts for 1.64% of the portfolio, ranked #19.

Foster Dykema Cabot & Partners first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $29.8M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Foster Dykema Cabot & Partners held 57,792 shares of Vertex Pharmaceuticals worth $25.8M as of Q1 2026.
Foster Dykema Cabot & Partners sold 552 Vertex Pharmaceuticals shares in Q1 2026, an estimated $257K.
Vertex Pharmaceuticals made up 1.64% of Foster Dykema Cabot & Partners's portfolio in Q1 2026, its #19 holding.
Foster Dykema Cabot & Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Foster Dykema Cabot & Partners's Vertex Pharmaceuticals position peaked at $29.8M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q1 2026, filed 14 May 2026.